Obsidian Therapeutics Inc (OBX)

$19.95 +2.42 (13.77%)
Market Cap 0.00
Revenue (ttm) 0.00
Net Income (ttm) -100.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 112,200
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 0.00
Stochastic %K 22%
Beta N/A
Analysts Strong Sell
Price Target $42.00
atmostrunmoney
atmostrunmoney Aug. 19 at 4:07 AM
$OBX Yea today it did .
0 · Reply
Zephix
Zephix Aug. 18 at 2:58 PM
$OBX
0 · Reply
BioCrazy1
BioCrazy1 Aug. 17 at 1:27 AM
$IOVA OT $OBX finding out rather quickly how the market and it's show me phase works.😁
1 · Reply
BioCrazy1
BioCrazy1 Aug. 17 at 1:24 AM
$OBX Yeah doing great!
0 · Reply
BioCrazy1
BioCrazy1 Aug. 17 at 1:22 AM
$OBX Saddle up for an ass kicking?
0 · Reply
OldGoldHawkeye
OldGoldHawkeye Aug. 16 at 2:39 PM
Iovance ($IOVA ) looks like the stronger long-term (20 year) hold compared to Obsidian ($OBX). IovanceI's Amtagvi, scaled manufacturing, regulatory track record and cash flow potential create advantages that build on themselves over time. Next generation programs can plug into an already working platform rather than starting from scratch. Obsidian has impressive early data and a differentiated approach that could still deliver big value. But even if its product ends up superior in some ways, first movers in this space often keep the durable moat and stay successful. See Imbruvica and Yescarta. That edge grows stronger when the first mover also has next generation assets like IOV-5001 advancing in the pipeline. The combination of established commercial presence and ongoing innovation tilts the long-term outlook toward Iovance. The structural edge feels clear - not a close call. I am long, and thus biased to, $IOVA.
0 · Reply
Market_Pulse_Report
Market_Pulse_Report Aug. 14 at 12:51 PM
$OBX
0 · Reply
jobix
jobix Aug. 14 at 4:19 AM
$OBX soon ,we will find out the difference between boys and men in this melanoma space. Iova is the clear leader here.
0 · Reply
Market_Pulse_Report
Market_Pulse_Report Aug. 14 at 1:50 AM
$OBX Check out this great video overview on all of the FINANCIALS!!!! MERGER!!! https://youtu.be/oAvqAFHtZrQ?si=M3F6nmxqJ24sovBH
0 · Reply
JFais
JFais Aug. 13 at 8:49 PM
$OBX (NP) $IOVA competitor in TIL on radar after today's decline (at least for DD list to learn more) No IL2 administration= could be given outpatient Guiding for topline data from registration-enabling cohort in melanoma by year-end 2027 (admittedly, VERY far behind Amtagvi + has to contend with $REPL Tudriqev and $IMTX anzu-cel)
2 · Reply
Latest News on OBX
Obsidian Therapeutics initiated with an Outperform at LifeSci Capital

2026-08-18T10:25:26.000Z - 1 day ago

Obsidian Therapeutics initiated with an Outperform at LifeSci Capital

Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause

2026-08-17T07:27:06.000Z - 2 days ago

Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause

Obsidian Therapeutics, Inc. Common Stock trading resumes

2026-08-17T07:26:47.000Z - 2 days ago

Obsidian Therapeutics, Inc. Common Stock trading resumes

Obsidian Therapeutics, Inc. Common Stock trading resumes

2026-08-10T15:20:09.000Z - 8 days ago

Obsidian Therapeutics, Inc. Common Stock trading resumes

Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause

2026-08-10T15:10:08.000Z - 8 days ago

Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause

Obsidian Therapeutics initiated with a Buy at TD Cowen

2026-08-06T09:50:48.000Z - 13 days ago

Obsidian Therapeutics initiated with a Buy at TD Cowen

Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause

2026-08-05T14:36:38.000Z - 13 days ago

Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause

Obsidian Therapeutics, Inc. Common Stock trading resumes

2026-08-05T14:35:45.000Z - 13 days ago

Obsidian Therapeutics, Inc. Common Stock trading resumes

Obsidian announces first patient enrolled in Phase 1/2 Agni-01 study

2026-08-05T11:47:11.000Z - 13 days ago

Obsidian announces first patient enrolled in Phase 1/2 Agni-01 study

Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma

Aug 5, 2026, 7:05 AM EDT - 14 days ago

Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma

Obsidian Therapeutics initiated with an Overweight at Piper Sandler

2026-08-05T08:30:27.000Z - 14 days ago

Obsidian Therapeutics initiated with an Overweight at Piper Sandler

Obsidian Therapeutics initiated with an Overweight at Piper Sandler

2026-08-04T23:30:21.000Z - 14 days ago

Obsidian Therapeutics initiated with an Overweight at Piper Sandler

Obsidian Therapeutics announces closing of transaction with Galera Therapeutics

2026-08-04T09:05:40.000Z - 15 days ago

Obsidian Therapeutics announces closing of transaction with Galera Therapeutics

atmostrunmoney
atmostrunmoney Aug. 19 at 4:07 AM
$OBX Yea today it did .
0 · Reply
Zephix
Zephix Aug. 18 at 2:58 PM
$OBX
0 · Reply
BioCrazy1
BioCrazy1 Aug. 17 at 1:27 AM
$IOVA OT $OBX finding out rather quickly how the market and it's show me phase works.😁
1 · Reply
BioCrazy1
BioCrazy1 Aug. 17 at 1:24 AM
$OBX Yeah doing great!
0 · Reply
BioCrazy1
BioCrazy1 Aug. 17 at 1:22 AM
$OBX Saddle up for an ass kicking?
0 · Reply
OldGoldHawkeye
OldGoldHawkeye Aug. 16 at 2:39 PM
Iovance ($IOVA ) looks like the stronger long-term (20 year) hold compared to Obsidian ($OBX). IovanceI's Amtagvi, scaled manufacturing, regulatory track record and cash flow potential create advantages that build on themselves over time. Next generation programs can plug into an already working platform rather than starting from scratch. Obsidian has impressive early data and a differentiated approach that could still deliver big value. But even if its product ends up superior in some ways, first movers in this space often keep the durable moat and stay successful. See Imbruvica and Yescarta. That edge grows stronger when the first mover also has next generation assets like IOV-5001 advancing in the pipeline. The combination of established commercial presence and ongoing innovation tilts the long-term outlook toward Iovance. The structural edge feels clear - not a close call. I am long, and thus biased to, $IOVA.
0 · Reply
Market_Pulse_Report
Market_Pulse_Report Aug. 14 at 12:51 PM
$OBX
0 · Reply
jobix
jobix Aug. 14 at 4:19 AM
$OBX soon ,we will find out the difference between boys and men in this melanoma space. Iova is the clear leader here.
0 · Reply
Market_Pulse_Report
Market_Pulse_Report Aug. 14 at 1:50 AM
$OBX Check out this great video overview on all of the FINANCIALS!!!! MERGER!!! https://youtu.be/oAvqAFHtZrQ?si=M3F6nmxqJ24sovBH
0 · Reply
JFais
JFais Aug. 13 at 8:49 PM
$OBX (NP) $IOVA competitor in TIL on radar after today's decline (at least for DD list to learn more) No IL2 administration= could be given outpatient Guiding for topline data from registration-enabling cohort in melanoma by year-end 2027 (admittedly, VERY far behind Amtagvi + has to contend with $REPL Tudriqev and $IMTX anzu-cel)
2 · Reply
pradorntadii00
pradorntadii00 Aug. 13 at 5:19 PM
$OBX is IOVA competitor in the next 4-5 year, added to watchlist and lay down watching bull run on IOVA till OBX show better data.
0 · Reply
stockanalysis_
stockanalysis_ Aug. 13 at 3:18 PM
Losers Today 1. $LESL -43.52% 2. $FGL -37.72% 3. $OBX -32.80% 4. $CLBT -31.02% 5. $OTLK -24.07% View this screener: https://stockanalysis.com/markets/losers/
0 · Reply
fffagygfcqdvc
fffagygfcqdvc Aug. 13 at 2:36 PM
$IOVA $OBX crashing.
5 · Reply
atmostrunmoney
atmostrunmoney Aug. 11 at 12:44 PM
$OBX This one is been a pleasant surprise.
1 · Reply
atmostrunmoney
atmostrunmoney Aug. 6 at 12:45 PM
$OBX TD Cowans initiated a buy saddle up….
1 · Reply
Merlintrader
Merlintrader Aug. 5 at 2:53 PM
Biotech Radar — August 5, 2026: $OBX, $ACRV and $URGN Lead a Broad Clinical and Capital-Markets Tape https://www.merlintrader.com/biotech-radar-august-5-2026-obx-acrv-urgn/
0 · Reply
YungBullHOLLA
YungBullHOLLA Aug. 5 at 11:57 AM
$OBX hey lil step bros Daddy IOVA is still your daddy
0 · Reply
beppels
beppels Aug. 5 at 11:26 AM
$GRTX $OBX , news! https://www.stocktitan.net/news/OBX/obsidian-therapeutics-announces-first-patient-enrolled-in-the-4gwefe44vsu1.html
1 · Reply
Gluteshevaa
Gluteshevaa Aug. 5 at 8:59 AM
$OBX trash. Maria, shame on you
0 · Reply
beppels
beppels Aug. 5 at 7:29 AM
$GRTX BEPPELS WL 05.08.: - $OBX, 29.6 $, 780 k float, merger with $GRTXD, uplist yesterday from OTC, last merger play $YAWR went 24 to 40 so far! ✅ - $KWM, 2.5 $, 2.57 mln float, had big news yesterday and still got crushed, ripping in overnite! ✅ - $TC, 1.98 $, 440 k float, 4.7 $ cash per share, 920 % ctb, 8 k to borrow! ✅ - $ZCMD, 1.05 $, 5.7 mln float, China low float at lows! ✅ - BYND 0.65 $, earnings ah today, cult stock, could run into earnings! ✅ Also watch PCLA, NIKI, QH, LFS, GITS, BRAI! 👀 🔥 👀​
0 · Reply
Kblek
Kblek Aug. 5 at 6:03 AM
$OBX
0 · Reply
jobix
jobix Aug. 5 at 4:41 AM
$OBX bearish!
0 · Reply